FREMONT, Calif., Feb 18, 2010 (BUSINESS WIRE) -- ARYx Therapeutics Inc. (NASDAQ: ARYX), a biopharmaceutical company, today announced that it has retained Cowen and Company to explore strategic options ...

FREMONT, Calif., Oct 07, 2009 (BUSINESS WIRE) -- ARYx Therapeutics, Inc. (NASDAQ:ARYX), a biopharmaceutical company, today announced that it has secured a committed equity financing facility under ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

NEW YORK (AP) – Biopharmaceutical company Aryx Therapeutics Inc. plans an initial public offering of its common stock, according to a regulatory filing Thursday with the Securities and Exchange ...

Aryx Therapeutics had its biggest drop in U.S. trading since going public 20 months ago after announcing that its anticoagulant drug wasn’t more effective than the existing drug warfarin in a study.

The Food and Drug Administration told Aryx Therapeutics Inc. it can start clinical testing of a drug aimed at schizophrenia. Fremont-based Aryx (NASDAQ: ARYX) has started giving the drug to healthy ...

Lead gastrointestinal drug poised for Phase III, but financing hasn’t yet been secured. ARYx Therapeutics last night confirmed terminating the employment of all its remaining staff and officers and ...

FDA delays giving guidance on late-stage trial design Co says investors withdrew funding arrangements Wind down to begin immediately (Adds details) March 9 (Reuters) - ARYx Therapeutics Inc said it ...

ARYx Therapeutics Inc. said Wednesday that because of a longer than expected delay in a drug decision from the Food and Drug Administration, it will begin winding down operations. ARYx Therapeutics ...

ARYx is floored by the decision, since Phase II trials were successful. Procter & Gamble Pharmaceuticals (P&G) has decided to nix its support of ARYx Therapeutics’ therapy for chronic constipation and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

ARYx Therapeutics Inc. Annual cash flow by MarketWatch. View ARYX net cash flow, operating cash flow, operating expenses and cash dividends.